Moreover, incretin-based therapies, such as treatment with dipeptidyl peptidase 4 (DPP-4) inhibitors, which might impact autophagy, are considered as critical approaches for the treatment of obesity [90]. Here, DPP4 is linked to obesity due to melanocortin 4 receptor deficiency.